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Abstract 
Objectives:  As the absence of Aβ related memory decline in apolipoprotein E (APOE) 
ε4 non-carriers may be due to the relative brevity of previous studies, we aimed to 
characterize Aβ related cognitive decline over 72-months in APOE ε4 carriers and non-
carriers who were cognitively normal (CN). 
Methods:  CN older adults (n=423) underwent Aβ imaging, and APOE genotyping.  
Participants completed comprehensive neuropsychological testing at baseline 18-, 36-, 
54- and 72-month assessments.  
Results:  Relative to Aβ- CN ε4 non-carriers, both Aβ+ CN ε4 carriers and non-carriers 
showed significantly increased decline in measures of memory, language, and executive 
function as well as higher rates of progression to a clinical classification of mild 
cognitive impairment (MCI).   Memory decline was greater in Aβ+ CN ε4 carriers than in 
Aβ+ CN ε4 non-carriers.  No cognitive decline was evident in Aβ- CN ε4 carriers.   
Conclusions:  In CN older adults, Aβ+ is associated with memory decline in ε4 non-
carriers; however, the rate of this decline is much slower than that observed in ε4 
carriers. These data indicate that the processes by which ε4 carriage increases the rate 
of Aβ-related cognitive decline occur in the preclinical stage of AD.  
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Introduction 
In cognitively normal (CN) older adults, both high amyloid (Aβ+) and carriage of 
the apolipoprotein E (APOE) ε4 allele increase risk for cognitive decline and dementia of 
the Alzheimer’s type (DAT),1-3 although the interaction between Aβ+ and ε4 carriage in 
the preclinical stages of AD is not understood.  Clinical studies show substantial 
cognitive decline over 54 months in Aβ+ CN ε4 carriers, particularly in episodic 
memory, compared to Aβ- CN ε4 non-carriers.  However, cognitive decline has not been 
observed in Aβ+ CN ε4 non-carriers4-6 suggesting that in preclinical AD, Aβ related 
cognitive decline is delayed in the absence of ε4.  This hypothesis is consistent with 
observations from epidemiological studies that in the absence of APOE ε4, the average 
age at which dementia is classified clinically is delayed by approximately 8 years.7, 8   
However, the nature and length of any such delay in preclinical AD is unknown.  
This study aimed to characterize the rate of Aβ-related cognitive decline over 72-
months in CN older adults who were ε4 carriers and non-carriers.  We hypothesized 
that compared to Aβ- CN ε4 non-carriers and Aβ+ CN ε4 non-carriers, Aβ+ CN ε4 
carriers would show greater cognitive decline and higher rates of progression to mild 
cognitive impairment (MCI) over 72-months.   
Methods 
Participants 
 Cognitively normal (CN) older adults (n=767) volunteered to participate in the 
Australian Imaging, Biomarkers and Lifestyle (AIBL) Study, for which details of the 
recruitment and classification of cognitive health has been previously detailed.9, 10  
Briefly, participants were excluded from AIBL if they had a previous confirmed 
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diagnosis of schizophrenia; Parkinson’s disease; sleep apnea; depression (e.g., Geriatric 
Depression Score [GDS] of 6 or greater); cancer (except basal cell skin carcinoma) in the 
last two years; symptomatic stroke or uncontrolled diabetes, or current alcohol use 
exceeded four standard drinks per day for men or two per day for women.  This study 
focused on a sub-sample of CN older adults (n=423) who had undergone Aβ 
neuroimaging with positron emission tomography (PET) and APOE genotyping.  The 
demographic and clinical characteristics of the total and PET subsample are shown and 
compared in Table 1. 
All available neuropsychological, psychiatric and medical information for 
participants on all assessments were reviewed by an expert clinical panel to determine 
whether individuals’ classification remained as CN or whether they met diagnostic 
classification for MCI,11, 12  or AD.13  Clinical classifications were blinded to data obtained 
from Aβ imaging at all visits. 
Standard Protocol Approvals, Registrations, and Patient Consents 
The AIBL study was approved by the ethics committees of Austin Health, St. 
Vincent’s Health, Hollywood Private Hospital and Edith Cowan University. These 
institutions also ensured compliance of all study protocols.9   Informed consent was 
provided in writing prior to participation in any study procedure.  
Assessments 
PET neuroimaging and APOE ɛ4 genotyping 
PET Aβ imaging was conducted using one of three radioligands, that is, 
Pittsburgh Compound B (PiB), florbetapir or flutemetamol.  The acquisition protocol for 
each radioligand has been detailed previously.10, 14, 15  Briefly, a 30-minute acquisition 
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was started 40 minutes after PiB-injection, and 20-minute acquisitions were performed 
50 minutes after florbetapir injection and 90 minutes after flutemetamol injection.  For 
PiB acquisition, standardized uptake value (SUV) data for key regions of interest were 
summed and normalized to the cerebellar cortex SUV. This resulted in a region-to-
cerebellar ratio which was termed SUV ratio (SUVR). For florbetapir, SUVR was 
generated using the whole cerebellum as the reference region,16 and for flutemetamol, 
the pons was used as the reference region. Consistent with previous studies, Aβ status 
was classified as either low (Aβ-) or high (Aβ+).  For PiB, an SUVR threshold ≥1.5 was 
used.10, 15  For florbetapir and flutemetamol,  an SUVR threshold of ≥1.1 and ≥0.62 were 
employed to discriminate between Aβ- and Aβ+, in accord with results of phase III 
studies.16  
An 80ml blood sample was taken from each participant, a sample of which was 
forwarded for DNA extraction using either QIAamp DNA blood Midi or Maxi kits 
(Qiagen) in accord with the protocol provided by the manufacturer.  APOE genotype was 
determined through TaqMan genotyping assays (Life Technologies) for rs7412 (Assay 
ID: C____904973_10) and rs429358 (Assay ID: C___3084793_20) on a QuantStudio 12K-
Flex real-time PCR system (Applied Biosystems) using the TaqMan GTXpress Master 
Mix (Life Technologies) methodology per manufacturer’s instructions. 
Neuropsychological testing 
To compute composite cognitive scores, first, each outcome measure on each 
neuropsychological test was standardized using the baseline mean and SD for the total 
CN group.  Composite scores were then formed by averaging standardized scores for 
episodic memory (California Verbal Learning Test, Second Edition [CVLT-II] delayed 
recall, Logical Memory delayed recall and Rey Complex Figure Test delayed recall); 
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executive function (Category Fluency Fruit/Furniture Switching and Letter Fluency); 
language (Boston Naming Test and Category Fluency Animals/Boys’ Names total score); 
and attention (Digit Symbol and Digit Span).  We have previously detailed the rationale, 
development and validation for each cognitive composite score.17, 18 
Procedure 
Upon enrolment into AIBL, all participants underwent detailed medical, 
psychiatric, and neuropsychological assessment.  These same assessments were 
repeated at 18-month intervals.  In this study, we report PET neuroimaging and APOE 
ε4 genotyping data obtained at a single assessment, and neuropsychological data 
obtained at the baseline, 18-, 36-, 54- and 72-month assessments. 
Data Analysis 
 To examine relationships between group (Aβ- CN ε4 non-carrier, Aβ- CN ε4 
carrier, Aβ+ CN ε4 non-carrier, Aβ+ CN ε4 carrier) and time (baseline, and 18, 36, 54 
and 72 month follow-up) for each composite cognitive score, we conducted a series of 
analyses using linear mixed effects models (LMM) with an unstructured covariance 
matrix and maximum likelihood estimation.  The linear mixed modelling approach was 
employed because it is robust to missing data (see Figure 1 for number of participants 
who withdrew from the study or had deceased), because it can model both fixed and 
random effects, thus accounting for multiple sources of variability, and because it 
provides improved estimates of random effects (within-subject coefficients) in 
prospective studies.  For each LMM, the cognitive composite score was the dependent 
variable. Group, time, and the interaction between group and time were specified as 
fixed factors; participant was specified as a random factor; and age, and anxiety 
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symptoms as the only covariates. Group mean slopes were computed for each cognitive 
composite score to reflect estimates of the rate of cognitive change over time.  Where 
LMMs indicated an interaction between group and time as statistically significant, 
estimates of slope in the Aβ- CN ε4 carriers, Aβ+ CN ε4 non-carriers, and Aβ+ CN ε4 
carriers were compared to that in the Aβ- CN ε4 non-carriers. Differences between 
slopes were expressed using Cohen’s d.  To provide context for any differences in 
memory decline observed between study groups, a criterion for clinically-significant 
memory impairment was defined as performance <1.5 SD below that of Aβ- ε4 non-
carriers.  The amount of time estimated for memory performance to reach this criterion 
was computed for each study group based on their LMM-derived linear functions. 
Results 
Demographic and clinical characteristics 
There were no significant differences between the demographic and clinical 
characteristics of the total CN sample and the PET subsample, as the 95% confidence 
intervals for each outcome measure overlap (Table 1).  
Statistically significant differences between Aβ/ε4 groups were observed for age 
and anxiety symptoms at baseline (Table 1).  Consequently, age and anxiety symptoms 
were entered as covariates in the LMMs.  Groups did not differ significantly on any other 
demographic or clinical characteristic at baseline. 
Effect of Aβ and ɛ4 on cognitive change  
Table 2 provides a summary of the group mean slopes for each cognitive 
composite for each Aβ/ε4 group.  Compared to Aβ- CN ε4 non-carriers, Aβ+ CN ε4 
carriers showed a significantly increased decline on all cognitive composites, and the 
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magnitudes of these differences were moderate-to-large (Figures 2 and 3).   However, 
compared to Aβ+ CN ε4 non-carriers, Aβ+ CN ε4 carriers showed a significantly 
increased decline only on the measure of episodic memory, and the magnitude of this 
difference was large.  
Compared to Aβ- CN ε4 non-carriers, Aβ+ CN ε4 non-carriers also showed a 
faster rate of decline for the measures of episodic memory, language and executive 
function (Figure 3).  The rate of decline in episodic memory in Aβ+ CN ε4 carriers 
indicated that the memory performance of this group would be severe enough to meet 
criterion for clinically-significant impairment in approximately 10 years (95%CI 6-18 
years), as opposed to 27 years (95%CI 10-45 years) in Aβ+ CN ε4 non-carriers.  
Compared to Aβ+ CN ε4 non-carriers, Aβ+ CN ε4 carriers showed an increased rate of 
decline only for episodic memory (Figure 3).  Group mean slopes of Aβ- CN ε4 non-
carriers and Aβ- CN ε4 carriers did not differ significantly on any cognitive composite.  
Effect of Aβ and ɛ4 on rates of disease progression  
At the 72-month assessment, the rate of clinical reclassification from CN to 
MCI/AD was significantly greater for Aβ+ CNs (18%) than for Aβ- CNs (6%), χ2=9.91, 
p<.001, Cramér’s V=.17 (Figure 1). However, while the rate of clinical reclassification 
from CN to MCI/AD was greater in Aβ+ CN ε4 carriers (22%) than Aβ+ CN ε4 non-
carriers (15%), this difference was not large enough to reach statistical significance, 
χ2=0.49, p=.49, Cramér’s V=.09.  
Discussion 
The hypothesis that Aβ+ CN ε4 carriers would show an increased rate of 
cognitive decline and greater rates of progression to MCI/AD compared to Aβ- CN ε4 
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non-carriers and Aβ+ CN ε4 non-carriers was supported.  Compared to Aβ- CN non-
carriers, Aβ+ CN ε4 carriers showed decline in all cognitive domains, although this was 
greatest for episodic memory (Figures 2-3).  Compared to Aβ+ CN ε4 non-carriers, Aβ+ 
CN ε4 carriers also showed a faster rate of decline in episodic memory, which was, by 
convention also large in magnitude (Table 2, Figure 2).  The exacerbation of Aβ-related 
memory decline by ε4 is both consistent with, and extends, the results of previous 
analyses of AIBL data over shorter periods 5, 6 and also from other cohorts,4 that ε4 
carriage increases the rate of Aβ-related memory decline over 18 to 54-months.  It is 
also consistent with animal studies which show that in the presence of Aβ+, the apoE4 
isoform causes cognitive impairment.  No such impairment is observed in the presence 
of the apoE3 isoform.8, 19  The current results also characterize the much slower rate of 
development of Aβ-related memory decline in CN older adults who do not carry the 
APOE ε4 allele.   Previous analyses of data from Aβ+ CN older adults in AIBL conducted 
over shorter periods (e.g., 36 months) have observed that Aβ-related cognitive decline 
is restricted to episodic memory.17  In the current study, cognitive decline in Aβ+ CN 
older adults extended to executive function, language and attention, albeit with more 
subtle trajectories (Table 2).  We believe that the detection of Aβ-related decline in 
domains beyond memory, observed in the current study, was due to the larger sample 
size in this study and that individuals had been assessed over a much longer time 
interval than previously.  In this context, the observation that exacerbation of Aβ-
related cognitive decline by APOE ε4 was specific to episodic memory confirms the 
centrality of episodic memory dysfunction to early AD.  It is also consistent with 
previous studies which also observed that Aβ-related cognitive decline in preclinical AD 
occurs only for APOE ε4 carriers and only for episodic memory.4, 5  We believe that with 
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a longer study period, Aβ-related decline in cognitive functions other than memory will 
become evident in Aβ+ CN ε4 non-carriers. 
Previously, we have expressed the relevance of Aβ-related memory decline in CN 
older adults as the time required for a declining memory trajectory to reach a level of 
clinically-significant memory impairment, that is, memory impairment that would 
warrant consideration of a diagnosis of MCI.12 In this study, clinically significant 
memory impairment was defined as performance that is less than 1.5 standard 
deviations from matched controls (Figure 2 dashed horizontal line).5  Extrapolation of 
the rates of memory decline in this study suggest that the Aβ+ CN ε4 carriers would 
develop clinically-significant memory impairment approximately 10 years after their 
first assessment (Figure 2; see Table 1 for baseline demographic characteristics of this 
group).  In contrast, Aβ+ CN ε4 non-carriers would require 27 years to reach the same 
criterion.  Consistent with these estimates of a relatively slow decline in cognition, only 
18% of the Aβ+ CN group were classified as having met clinical criteria for MCI or AD 
over the study period of 72-months, and this proportion was only slightly greater in ε4 
carriers (22%) than in non-carriers (15%) (Figure 1).  These data reflect the subtlety of 
Aβ-related cognitive decline observed in current preclinical AD groups and suggest that 
study over even longer intervals may be required to determine the effect of APOE ε4 
carriage on clinical progression in Aβ+ CN older adults. 
There is increasing evidence from both human and animal studies that the apoE4 
isoform affects risk for AD by disrupting Aβ clearance relative to the other apoE 
isoforms (i.e., apoE3 and apoE2).7, 8, 20, 21  Further, apoE4 itself has also been implicated 
directly in neurodegeneration and reduced synaptic integrity,22 such that even a modest 
increase in apoE4 levels can increase Aβ accumulation and exacerbate synaptic loss 
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around plaques. 23  However, it is not clear whether the processes by which apoE4 
affects risk for AD are through an increase in neurotoxicity, loss in neuroprotective 
function, or combination of both.21  While the processes by which apoE4 increases risk 
for AD may occur independently of Aβ, it is also likely that Aβ oligomers can further 
impair the physiological functions of apoE in promoting synaptic and neuronal 
integrity.24  Thus, the absence of the APOE ε4 allele may afford some level of protection 
against AD-related neurodegeneration even when the amyloid cascade has begun (i.e., 
Aβ accumulation).  The substantial delay in Aβ-related memory impairment observed in 
the current CN group suggests that understanding and manipulating the biological 
processes by which apoE4 exacerbates Aβ toxicity could provide important insight into 
the pathogenesis of AD and perhaps even a basis for the development of 
pharmacotherapies to reduce this toxicity and its clinical consequences.  The 
observation in the current study that ε4 carriage accounted for more than 18% of 
additional variance in Aβ-related cognitive decline suggests strongly that clinical trials 
of preclinical AD should consider stratification of their Aβ+ samples according to APOE 
ε4 carriage. 
While the risk for AD and high levels of Aβ posed by APOE ε4 carriage have now 
been documented consistently,10, 25 the results of this study suggest that in the absence 
of Aβ, APOE ε4 carriage does not increase risk for cognitive decline.  Despite the 
comparatively large sample, the long period of investigation and the sensitive 
neuropsychological tasks used, we observed no effect of ε4 carriage on cognitive decline 
independent of Aβ+.  All aspects of cognitive function remained stable in Aβ- CN ε4 
carriers, and the rate of change of Aβ- CN ε4 carriers over the 72-month test-retest 
period was indistinguishable from that of Aβ- CN ε4 non-carriers (Figure 2 and Table 2). 
The observation that in Aβ-, ε4 carriage is not associated with any cognitive decline has 
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been reported previously in the AIBL and other cohorts of CN older adults whose Aβ 
status is known.4-6  While a series of large and well-designed prospective studies have 
shown that carriage of the APOE ε4 allele is associated with increased decline in 
cognitive function, a major limitation of these studies has been that the Aβ status of 
their samples was unknown.26  It is therefore likely that the decline in cognitive function 
observed previously in ε4 carriers reflected the effects of both Aβ+ and ε4 carriage, 
rather than any independent effect of ε4 by itself.  
When considering the results of this study, an important caveat is that the AIBL 
study, like many other natural history early AD cohorts,27, 28 is not a population-based 
sample.  In AIBL, few CN older adults had existing or untreated medical, neurological or 
psychiatric illnesses and most participants were highly educated.  As such, it will be 
important for the results of the current study to be replicated in other early AD cohorts, 
especially in study groups whose ascertainment has been based on epidemiological 
principles (e.g., the Mayo Clinic Study of Aging).29  A second caveat is that participants 
underwent neuroimaging at varying timepoints after their baseline assessment, with 
the median delay between neuropsychological testing and Aβ neuroimaging 3 years.  
However, as current empirical models of AD have shown that the rate of Aβ 
accumulation is very slow, particularly in the preclinical stage of the disease,3, 30 it is 
unlikely that individuals classified as Aβ+ at the 36-month assessment were Aβ- at the 
baseline assessment.  To test this assumption, the main statistical models were re-
computed with the time lag between baseline neuropsychological assessment and PET 
scan entered as a covariate. This reanalysis revealed no statistically significant effect for 
the time lag (Supplementary Table 1). Further, estimates of slopes for each Aβ/ε4 group 
also did not change substantially.  We now await the completion of sequential amyloid 
scans in the entire AIBL CN cohort so as to appreciate, more accurately, the relationship 
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between cognitive change and Aβ accumulation in ε4 carriers and non-carriers. 
Nonetheless, it will be prudent for future studies to determine whether individuals who 
transition from Aβ- to Aβ+ show a different cognitive profile to those who remain Aβ- or 
Aβ+ across a study period. However, our current data suggest that the additive effect of 
Aβ+ and ɛ4 on cognitive decline in preclinical AD may make an ideal target for 
pharmaceutical therapies that mitigate Aβ-related neurodegeneration, or from the 
interaction between Aβ+ and ɛ4.  They further support the hypothesis that reducing the 
toxic effects of apoE4 or restoring the neuroprotective functions of apoE isoforms in 
promoting synaptic plasticity and reducing neuroinflammation may be viable 
therapeutic strategies for the future.21 
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Table 1. Demographic and clinical characteristics. 
 CN total sample 
(n=767) 
PET subsample 
(n=423) 
 CN Aβ- non-ε4 
(n=262) 
CN Aβ- ε4 
(n=64) 
CN Aβ+ non-ε4  
(n=46) 
CN Aβ+ ε4  
(n=51) 
p 
% Female 
[95% CI] 
439 (57%) 
[52-62%] 
231 (55%) 
[49-61%] 
 142 (54%) 37 (58%) 23 (50%) 29 (57%) .854 
% APOE ε4 
[95% CI] 
207 (27%) 
[21-33%] 
115 (27%) 
[19-35%] 
 - - - - - 
Age Mean (SD) 
[95% CI] 
70.03 (7.00) 
(69.53-70.53) 
69.39 (6.60) 
(68.76-70.02) 
 68.59 (6.03) 66.97 (5.47) 75.02 (7.37) 71.45 (6.82) .000 
Premorbid IQ Mean (SD) 
[95%CI] 
108.28 (7.27) 
[107.77-108.79] 
108.66 (7.08) 
[107.99, 109.33] 
 108.44 (6.94) 107.56 (7.59) 110.63 (7.62) 109.37 (6.43) .118 
GDS Mean (SD) 
[95% CI] 
0.98 (1.39) 
[0.88-1.08] 
0.87 (1.33) 
[0.74, 1.00] 
 0.91 (1.38) 0.98 (1.49) 0.61 (1.08) 0.73 (1.08) .406 
HADS-D Mean (SD) 
[95% CI] 
2.58 (2.24) 
[2.42, 2.74] 
2.62 (2.32) 
[2.40, 2.84] 
 2.57 (2.24) 2.77 (2.04) 2.02 (1.69) 3.22 (3.24) .080 
HADS-A Mean (SD) 
[95% CI] 
4.30(2.95) 
[4.09, 4.51] 
4.28 (2.85) 
[4.01, 4.55] 
 4.29 (2.84) 4.13 (2.89) 3.42 (1.97) 5.18 (3.31) .025 
MACQ Mean (SD) 
[95% CI] 
25.19 (4.32) 
[24.88, 25.50] 
25.21 (4.41) 
[24.79, 25.63] 
 24.79 (4.32) 25.98 (3.86) 25.71 (4.87) 26.01 (4.96) .110 
CDR Mean (SD) 
[95% CI] 
0.03 (0.12) 
[0.02, 0.04] 
0.03 (0.13) 
[0.02, 0.04] 
 0.03 (0.11) 0.04 (0.14) 0.07 (0.20) 0.02 (0.10) .187 
CDR sum of boxes Mean (SD) 
[95% CI] 
0.03 (0.15) 
[0.02, 0.04] 
0.03 (0.15) 
[0.02, 0.04] 
 0.03 (0.16) 0.04 (0.14) 0.04 (0.14) 0.02 (0.10) .852 
MMSE Mean (SD) 
[95% CI] 
28.86 (1.19) 
[28.78, 28.94] 
28.92 (1.16) 
[28.81, 29.03] 
 28.97 (1.13) 28.90 (1.21) 28.85 (1.25) 28.75 (1.18) .627 
Note: CN = cognitively normal older adults; APOE = apolipoprotein E; GDS = Geriatric Depression Scale; HADS = Hospital Anxiety and 
Depression Scale; MACQ = Memory Complaints Questionnaire; CDR = Clinical Dementia Rating scale; MMSE = Mini Mental State 
Examination 
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Table 2. Effect of Aβ and ε4 on each cognitive composite score over 72-months in CN older adults  
 Episodic Memory Executive Function Language Attention 
 (df) F p (df) F p (df) F p (df) F p 
Age (1,418) 41.75 .000 (1,419) 31.87 .000 (1,423) 25.74 .000 (1,421) 65.49 .000 
Anxiety (1,415) 0.69 .408 (1,412) 0.33 .569 (1,419) 1.64 .201 (1,418) 1.92 .167 
Group (3,421) 0.47 .701 (3,426) 2.52 .057 (3,425) 1.78 .150 (3,427) 4.28 .005 
Time (1,360) 11.78 .000 (1,392) 33.32 .000 (1,331) 30.61 .000 (1,404) 41.67 .000 
Group x Time (3,356) 19.42 .000 (3,386) 3.89 .009 (3,327) 6.45 .000 (3,401) 4.96 .002 
         
 Mean Slope SD Mean Slope SD Mean Slope SD Mean Slope SD 
CN Aβ- ε4-  (n=262) 0.024 0.161 -0.048 0.173 -0.022 0.157 -0.045 0.176 
CN Aβ- ε4+ (n=64) 0.044 0.131 -0.008 0.141 -0.006 0.128 -0.015 0.143 
CN Aβ+ ε4- (n=46) -0.043 0.129 -0.100 0.139 -0.086 0.126 -0.115 0.139 
CN Aβ+ ε4+ (n=51) -0.173 0.134 -0.112 0.139 -0.120 0.131 -0.123 0.143 
*Note: All models have been adjusted for age and the Hospital Anxiety and Depression Scale (HADS) Anxiety subscale score; Group 
indicates group membership as Aβ- ε4-, Aβ- ε4+, Aβ+ ε4- or Aβ+ ε4+ 
**Note: CN = Cognitively normal; ε4- = ε4 non-carriers; ε4+ = ε4 carriers   
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Supplementary Table 1. Effect of Aβ and ε4 on each cognitive composite score over 72-months in CN older adults, after accounting for 
time lag between baseline neuropsychological assessment and PET scan  
 Episodic Memory Executive Function Language Attention 
 (df) F p (df) F p (df) F p (df) F p 
Age (1,417) 38.85 .000 (1,417) 27.52 .000 (1,421) 21.50 .000 (1,420) 58.53 .000 
Anxiety (1,415) 0.68 .409 (1,412) 0.35 .552 (1,419) 1.71 .191 (1,418) 1.95 .163 
Scan Time Lag (1,416) 0.00 .983 (1,410) 0.64 .426 (1,418) 0.91 .342 (1,418) 0.30 .584 
Group (3,422) 0.47 .703 (3,428) 2.40 .067 (3,427) 1.74 .159 (3,429) 4.05 .007 
Time (1,360) 11.78 .001 (1,392) 33.54 .000 (1,331) 30.67 .000 (1,404) 41.74 .000 
Group x Time (3,356) 19.42 .000 (3,386) 3.92 .009 (3,327) 6.47 .000 (3,401) 4.97 .002 
         
 Mean Slope SD Mean Slope SD Mean Slope SD Mean Slope SD 
CN Aβ- ε4-  (n=262) 0.024 0.161 -0.049 0.173 -0.022 0.157 -0.046 0.176 
CN Aβ- ε4+ (n=64) 0.044 0.131 -0.008 0.141 -0.006 0.128 -0.015 0.143 
CN Aβ+ ε4- (n=46) -0.043 0.129 -0.101 0.139 -0.086 0.126 -0.115 0.139 
CN Aβ+ ε4+ (n=51) -0.173 0.134 -0.112 0.143 -0.120 0.131 -0.123 0.143 
*Note: All models have been adjusted for age, amount of time lag between baseline neuropsychological assessment and PET scan, and 
the Hospital Anxiety and Depression Scale (HADS) Anxiety subscale score; Group indicates group membership as Aβ- ε4-, Aβ- ε4+, Aβ+ 
ε4- or Aβ+ ε4+ 
**Note: CN = Cognitively normal; ε4- = ε4 non-carriers; ε4+ = ε4 carriers
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Figure Captions 
Figure 1. Clinical classification and disease progression of CN Aβ- and CN Aβ+ 
participants over 72 months. 
Figure 2. Trajectories of Episodic Memory change over 72 months.   
Dotted line indicates 1.5 SD decline for clinically-significant memory impairment. Error 
bars represent the 95% confidence intervals of the difference in the rate of cognitive 
change. 
Figure 3. Magnitude of difference (Cohen’s d) in the rate of cognitive change over 72 
months. 
Magnitude of difference (Cohen’s d) in the rate of change in each cognitive composite 
score between CN Aβ- ε4 carriers, CN Aβ+ ε4 non-carriers, and CN Aβ+ ε4 carriers 
relative to CN Aβ- ε4 non-carriers (represented by “0” line).  Error bars represent the 
95% confidence intervals of the difference in the rate of cognitive change. 
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